🔎 Today’s Daily Sift: Longevity Longevity has escaped the wellness aisle and entered the operating system of modern capitalism. Today’s signal is clear: Aging is no longer being treated as inevitable. It is increasingly being treated like an engineering problem. AI driven biotech firms are accelerating the race toward therapies that target the biology of aging itself. Insilico Medicine expanded its longevity initiatives this week while regenerative medicine and cellular reprogramming continue moving closer to real human applications. The frontier is shifting from supplements to cellular engineering. Senolytics, therapies designed to remove aging “zombie cells,” are becoming one of biotech’s hottest categories. Meanwhile, partial cellular reprogramming using Yamanaka factors is no longer science fiction. Human trials are already underway. The hidden pattern: AI compresses drug discovery timelines while longevity research unlocks the largest possible market on Earth. At the same...